Initial Statement of Beneficial Ownership (3)
19 September 2020 - 6:15AM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Powell David Jonathan |
2. Date of Event Requiring Statement (MM/DD/YYYY)
9/18/2020
|
3. Issuer Name and Ticker or Trading Symbol
Summit Therapeutics Inc. [SMMT]
|
|
(Last)
(First)
(Middle)
C/O SUMMIT THERAPEUTICS INC.,, ONE BROADWAY, 14TH FLOOR |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
Chief Scientific Officer / |
|
(Street)
CAMBRIDGE, MA 02142
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4) | 2. Amount of Securities Beneficially Owned
(Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) | 4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4) | 2. Date Exercisable and Expiration Date
(MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) | 6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (right to buy) | (1) | 10/19/2028 | Common Stock | 84686 | $1.92 | D | |
| Stock Option (right to buy) | (2) | 3/29/2029 | Common Stock | 80000 | $1.79 | D | |
| Stock Option (right to buy) | (3) | 7/8/2030 | Common Stock | 300000 | $3.31 | D | |
| Explanation of Responses: |
| (1) | The option was granted on October 19, 2018. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date. |
| (2) | The option was granted on March 29, 2019. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date. |
| (3) | The option was granted on July 8, 2020. The shares underlying the option are scheduled to vest in four equal annual installments with the first installment occurring on the one year anniversary of the grant date, subject to the satisfaction of certain performance targets. |
Remarks:
Exhibit List: Exhibit 24 - Power of Attorney |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Powell David Jonathan
C/O SUMMIT THERAPEUTICS INC.,
ONE BROADWAY, 14TH FLOOR
CAMBRIDGE, MA 02142 |
|
| Chief Scientific Officer |
|
Signatures
|
| /s/ Michael Paul Donaldson, Attorney-in-Fact | | 9/18/2020 |
| **Signature of Reporting Person | Date |
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024
